Mark Agulnik, MD

Professor of Clinical Medicine

Vice Chair for Faculty Development, Department of Medicine

Section Chief of Sarcomas & Melanoma

Is this your profile? Click to edit

Publications

Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: a pilot study. Head Neck. 2015 Apr; 37(4):567-72.. View in PubMed
Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. Onco Targets Ther. 2014; 7:245-51.. View in PubMed
Assessment of multimodality therapy use for extremity sarcoma in the United States. J Surg Oncol. 2014 Apr; 109(5):395-404.. View in PubMed
Effect of recombinant human deoxyribonuclease on oropharyngeal secretions in patients with head-and-neck cancers treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):282-9.. View in PubMed
Bone cancer. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):688-723.. View in PubMed
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.. View in PubMed
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther. 2013; 6:135-43.. View in PubMed
Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013 Mar; 73(4):315-25.. View in PubMed
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan; 24(1):257-63.. View in PubMed
Advances in adjuvant therapy of gastrointestinal stromal tumors. Curr Oncol Rep. 2012 Aug; 14(4):327-32.. View in PubMed